JP2015535237A5 - - Google Patents

Download PDF

Info

Publication number
JP2015535237A5
JP2015535237A5 JP2015538612A JP2015538612A JP2015535237A5 JP 2015535237 A5 JP2015535237 A5 JP 2015535237A5 JP 2015538612 A JP2015538612 A JP 2015538612A JP 2015538612 A JP2015538612 A JP 2015538612A JP 2015535237 A5 JP2015535237 A5 JP 2015535237A5
Authority
JP
Japan
Prior art keywords
composition
phosphate
citrate buffer
pharmaceutical composition
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015538612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015535237A (ja
JP6431844B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/059612 external-priority patent/WO2014064637A1/en
Publication of JP2015535237A publication Critical patent/JP2015535237A/ja
Publication of JP2015535237A5 publication Critical patent/JP2015535237A5/ja
Application granted granted Critical
Publication of JP6431844B2 publication Critical patent/JP6431844B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015538612A 2012-10-26 2013-10-24 Tnfr:fc融合プロテインの安定な医薬組成物 Expired - Fee Related JP6431844B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN1236/KOL/2012 2012-10-26
IN1235/KOL/2012 2012-10-26
IN1235KO2012 2012-10-26
IN1236KO2012 2012-10-26
PCT/IB2013/059612 WO2014064637A1 (en) 2012-10-26 2013-10-24 Stable pharmaceutical composition of tnfr:fc fusion protein

Publications (3)

Publication Number Publication Date
JP2015535237A JP2015535237A (ja) 2015-12-10
JP2015535237A5 true JP2015535237A5 (enExample) 2016-12-15
JP6431844B2 JP6431844B2 (ja) 2018-11-28

Family

ID=54208810

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015538612A Expired - Fee Related JP6431844B2 (ja) 2012-10-26 2013-10-24 Tnfr:fc融合プロテインの安定な医薬組成物

Country Status (14)

Country Link
US (2) US10058589B2 (enExample)
EP (1) EP2919801B1 (enExample)
JP (1) JP6431844B2 (enExample)
KR (1) KR102132050B1 (enExample)
CN (1) CN104936607A (enExample)
AU (1) AU2013336279B2 (enExample)
BR (1) BR112015009462A2 (enExample)
CA (1) CA2889271A1 (enExample)
ES (1) ES2806946T3 (enExample)
MX (1) MX366622B (enExample)
PL (1) PL2919801T3 (enExample)
PT (1) PT2919801T (enExample)
RU (1) RU2664691C2 (enExample)
WO (1) WO2014064637A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
HK1221163A1 (zh) * 2013-05-02 2017-05-26 Mabxience, S.A. Tnfr:fc融合多肽的替代配方
JP6480154B2 (ja) * 2014-11-06 2019-03-06 持田製薬株式会社 エタネルセプトの凍結乾燥製剤
MX389818B (es) * 2015-08-13 2025-03-20 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
ES2962373T3 (es) * 2016-04-13 2024-03-18 Medimmune Llc Uso de aminoácidos como compuestos estabilizadores en composiciones farmacéuticas que contienen altas concentraciones de agentes terapéuticos basados en proteínas
ES3064802T3 (en) * 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same
CN111432880A (zh) * 2017-08-08 2020-07-17 瑞士杰特贝林生物制品有限公司 血色素结合蛋白制剂
CA3042126A1 (en) 2018-05-03 2019-11-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of treating kawasaki disease
WO2022264097A1 (en) 2021-06-17 2022-12-22 Lupin Limited Pharmaceutical composition of anti-tumour necrosis factor (anti-tnf) agent for management of infectious diseases caused by coronaviruses
CN122459015A (zh) * 2024-05-31 2026-07-24 荣昌生物制药(烟台)股份有限公司 环糊精及其衍生物作为保护剂在制备TACI-Fc融合蛋白液体药物制剂中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215743A (en) 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
DE4239877C1 (de) * 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
DK1017413T4 (da) * 1997-09-23 2008-03-25 Rentschler Biotech Gmbh Flydende formulering af interferon-beta
CA2476934C (en) * 2002-02-27 2009-06-16 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
EA009079B1 (ru) 2003-02-28 2007-10-26 Арес Трейдинг С.А. Жидкие составы фактор некроза опухоли-связывающих белков
ES2310122B1 (es) * 2007-04-20 2009-10-30 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
WO2009133529A2 (en) * 2008-04-30 2009-11-05 Wockhardt Research Centre Processes for refolding of insulin
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
RU2600847C2 (ru) 2010-05-10 2016-10-27 Интас Биофармасьютикалс Лимитед Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина
TWI603739B (zh) * 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗-TNFα抗體之液體調配物
RU2614257C2 (ru) * 2011-04-20 2017-03-24 Сандоз Аг СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ СЛИТОГО БЕЛКА TNFR:Fc

Similar Documents

Publication Publication Date Title
RU2015119603A (ru) Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc
JP2019536761A5 (enExample)
HRP20211417T1 (hr) Formulacije koje stabiliziraju i sprječavaju taloženje imunogenih pripravaka
FI3506886T3 (fi) Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä
JP2015527402A5 (enExample)
JP2019504086A5 (enExample)
JP2012515221A5 (enExample)
JP2018138578A5 (enExample)
JP2022166006A5 (enExample)
FI3209681T3 (fi) Peptidivariantteja käsittäviä farmaseuttisia koostumuksia ja niiden käyttömenetelmiä
JP2010529999A5 (enExample)
RU2020112952A (ru) Жидкая фармацевтическая композиция
JP2013521296A5 (enExample)
JP2013543505A5 (enExample)
JP2011502968A5 (enExample)
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
EA201891154A1 (ru) Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
RU2015132431A (ru) Составы, содержащие антитела
HRP20250382T1 (hr) Farmaceutski pripravak koji sadrži karbetocin
HRP20230929T1 (hr) Stabilni pripravci semaglutida i njihova upotreba
JP2017516848A5 (enExample)
RU2010141542A (ru) Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций
RU2017101667A (ru) Фармацевтические композиции
JP2015521593A5 (enExample)
JP2016539921A5 (enExample)